Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online meetings, and phone calls has predictably returned. But what can you do? The world, such as it is, keeps spinning. So time to give it a nudge in a better direction with a carefully brewed cup of stimulation. Our choice today is maple bourbon. Please feel free to join us. Meanwhile, we have assembled the usual line-up of interesting items to help you get started on your own journey. May it be meaningful and productive. And of course, do keep in touch. We treasure your saucy tips and keen insights. …
In a boost for Amgen, the U.S. Supreme Court agreed to hear a case in which the company argued a federal appeals court incorrectly determined its patent claims on a cholesterol medication are invalid, STAT tells us. At issue is a long-running battle between Amgen and a pair of rivals — Sanofi and Regeneron Pharmaceuticals — over the market for injectable cholesterol treatments. Amgen filed a lawsuit against the other companies in 2014 for allegedly infringing patents when they sought regulatory approval for their own medication. Both drugs won U.S. regulatory approval the subsequent year.
Some Eli Lilly employees have requested transfers from the company’s Indiana operations following a new law passed by the Republican-controlled state government to ban most abortions in the state, The Financial Times says. Lilly chief executive officer David Ricks confided that some staff asked to relocate outside the state even though an Indiana judge temporarily halted the proposed ban. The new rules created challenges for people to come and work in Indiana and if Lilly wants to attract and retain staff it has to grow elsewhere, he added. Ricks said the law was “rushed” and should have considered whether it would undermine the ability to recruit and retain talent from out of state.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect